Indian court's pricing policy warning spooks industry, activists upbeat
This article was originally published in Scrip
Executive Summary
The Supreme Court's tough stance against the Indian government over the delayed drug pricing policy and ambiguity over the court's observations on the methodology for price control has left the pharmaceutical industry jittery. Activists, though, appear upbeat about the prospects of a pro-patient regulation emerging.